CClinicalTrials.gg
Active, not recruitingNCT07804745Updated Sep 23, 2026

Fertility Decision and Outcomes in Young Women With Breast Cancer

An observational study in Breast Cancer - Female and Fertility, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Active, not recruiting at 3 sites in China. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
300
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

This observational study is to learn about the fertility outcomes and decision after breast cancer diagnosis, and the current status of fertility consultation and decision support in young women diagnosed with breast cancer in China.

02

Conditions studied

  • Breast Cancer - Female
  • Fertility

Browse trials for

Keywords

  • Breast Cancer
  • Fertility
  • Pregnancy
03

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Sampling method
Probability sample

Study population

This study will include female patients aged 18-40 years who were diagnosed with breast cancer between January 2013 and December 2023 at one of three participating centres in China: the Second Affiliated Hospital of Zhejiang University School of Medicine, Jilin Cancer Hospital, and Hangzhou First People's Hospital.

Eligible patients must have complete medical records and no child before cancer diagnosis.

Patients with stage IV disease at diagnosis, those with pre-existing infertility factors, or those with other malignancies, will be excluded. Patients who decline to participate or cannot be contacted for follow-up will also be excluded.

Inclusion criteria

  • Female breast cancer patients, aged 18-40 years at diagnosis.
  • Treated at the three participating hospitals between 1 January 2013 and 31 December 2023.
  • Complete clinical documentation available in the electronic medical record system.
  • Had no child before cancer diagnosis.

Exclusion criteria

Exclusion Criteria:

  • Prior reproductive compromise (surgical or diagnostic infertility or pre-existing infertility factors) before cancer diagnosis.
  • Presented with de novo stage IV (metastatic) disease.
  • Had a history of other malignancies.
  • Patients who refuse to participate or cannot be contacted for follow-up.
04

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Case Group (No childbearing after diagnosis)

    Patients diagnosed with breast cancer who had no live birth prior to diagnosis but had no live birth after diagnosis.

    Other: No intervention (observational study)

  • Control Group (Childbearing after diagnosis)

    Patients diagnosed with breast cancer who had no live birth prior to diagnosis but had at least one live birth after diagnosis.

    Other: No intervention (observational study)

Interventions

  • OtherNo intervention (observational study)

    This is an observational study. Our study is based on the real-world conditions. We don't have any intervention.

05

What researchers measure

Primary outcomes

  1. Childbearing after breast cancer diagnosis

    We will follow up with patients who had not given birth before their cancer diagnosis, to establish whether they had given birth by the end of follow-up. It will be assessed by patient self-report during follow-up and available medical records. The outcome will be recorded as a binary variable (yes/no).

    Time frame: Up to 2026

Secondary outcomes

  1. Fertility preservation measures uptake

    We will calculate the proportion of patients who underwent fertility preservation procedures in cases vs. controls.

    Time frame: up to 2026

  2. Multidisciplinary collaboration involvement

    We will calculate the proportion of patients with multidisciplinary team discussion or referral involving reproductive medicine, gynecology, or fertility specialists.

    Time frame: up to 2026

06

Study locations

3 sites
  • Jilin Cancer Hospital
    Changchun, Jilin, China
  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang, China
  • the Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
07

Registry details

Key details

Study ID
NCT07804745
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Collaborators
Jilin Provincial Tumor Hospital, First People's Hospital of Hangzhou
Responsible party
Sponsor
First posted
Sep 4, 2026
Start date
Oct 15, 2025
Primary completion
Sep 1, 2026
Completion
Oct 31, 2026 (estimated)
Last update
Sep 23, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion